Capricor Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Beverly Hills CA United States (2005)

Organization Overview

First Clinical Trial
2012
NCT01458405
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Capricor Inc. | Capricor Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

allogeneic cardiosphere-derived cells (8 trials)

Drugs in Phase 2 Trials (2)

Key: Capricor Inc. (0) Acquired (2)

cenderitide (3 trials)

chimeric natriuretic peptide (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 2)

Cardiomyopathy, Dilated (Phase 1)

Genetic Diseases, Inborn (Phase 2)

Genetic Diseases, X-Linked (Phase 2)

Heart Failure (Phase 2)

Infarction (Phase 2)

Muscular Diseases (Phase 2)

Muscular Disorders, Atrophic (Phase 2)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Myocardial Infarction (Phase 2)

Nervous System Diseases (Phase 2)

Neuromuscular Diseases (Phase 2)

Renal Insufficiency (Phase 2)

Ventricular Dysfunction (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 3